Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document.
Hector M Garcia-Garcia, Eugène P McFadden, Andrew Farb...
https://pubmed.ncbi.nlm.nih.gov/29891620/Actively Recruiting
Led by Chonnam National University Hospital · Updated on 2026-10-15
512
Participants Needed
1
Research Sites
52 weeks
Total Duration
This research aims to compare norepinephrine and dopamine as the first vasoactive drugs for treating cardiogenic shock in adults. Cardiogenic shock is a serious condition where the heart cannot pump enough blood, leading to tissue damage and high risk of death. The study evaluates which drug better stabilizes blood pressure, improves tissue perfusion, and prevents worsening shock during early treatment. Participants will be randomly assigned to receive either norepinephrine or dopamine through continuous intravenous infusion, following a specific dosing plan that adjusts based on their response and clinical condition. Both drugs are administered using infusion pumps in intensive care units, with treatment and monitoring following current clinical guidelines. The infusion duration depends on each participants stabilization. During the study, participants will undergo regular monitoring of blood pressure, heart rhythm, laboratory tests, and organ function while hospitalized. Researchers will follow participants for outcomes at 1 month, 6 months, and 1 year after enrollment. The main measure is a combination of death or worsening shock within 28 days. Additional outcomes include complications like arrhythmias, mechanical support needs, and rehospitalization. Safety and effectiveness will be assessed throughout the study period.
CONDITIONS
Assessing Catecholamine Treatment Initiation Options: Norepinephrine vs Dopamine for Cardiogenic Shock
M
Min Chul Kim, Professor, MD, PhD
Y
Yongwhan Lim, Professor, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Chonnam National University Hospital
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Varies by participant based on clinical stabilization
Participants receive either norepinephrine or dopamine as the first vasoactive drug for cardiogenic shock, with doses adjusted based on clinical response and monitoring.
Continuous monitoring during hospitalization
Duration - Up to 1 year after enrollment
Participants are followed up at 1 month, 6 months, and 1 year after enrollment for assessment of survival, complications, and heart and kidney function.
Scheduled follow-up visits or assessments
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Hector M Garcia-Garcia, Eugène P McFadden, Andrew Farb...
https://pubmed.ncbi.nlm.nih.gov/29891620/Veli-Pekka Harjola, Johan Lassus, Alessandro Sionis...
https://pubmed.ncbi.nlm.nih.gov/25820680/Shashank S Sinha, David A Morrow, Navin K Kapur...
https://pubmed.ncbi.nlm.nih.gov/40100174/Srihari S Naidu, David A Baran, Jacob C Jentzer...
https://pubmed.ncbi.nlm.nih.gov/39130139/Heather L Gornik, Herbert D Aronow, Philip P Goodney...
https://pubmed.ncbi.nlm.nih.gov/38743805/Alexandra J Lansky, Steven R Messé, Adam M Brickman...
https://pubmed.ncbi.nlm.nih.gov/28183511/Mohammed Osman, Moinuddin Syed, Saikrishna Patibandla...
https://pubmed.ncbi.nlm.nih.gov/34315234/Isabelle C Van Gelder, Michiel Rienstra, Karina V Bunting...
https://pubmed.ncbi.nlm.nih.gov/39210723/Arif Khwaja
https://pubmed.ncbi.nlm.nih.gov/22890468/Robert A Byrne, Xavier Rossello, J J Coughlan...
https://pubmed.ncbi.nlm.nih.gov/37622654/Chonnam National University Hospital
Lead Sponsor